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Abstract Among oncolytic viruses, the vesicular stomatitis
virus (VSV) is especially potent and a highly promising
agent for the treatment of cancer. But, even though effective
against multiple tumor entities in preclinical animal models,
replication-competent VSV exhibits inherent neurovirulence,
which has so far hindered clinical development. To overcome
this limitation, replication-defective VSV vectors for cancer
gene therapy have been tested and proven to be safe. Howev-
er, gene delivery was inefficient and only minor antitumor
efficacy was observed. Here, we present semireplication-
competent vector systems for VSV (srVSV), composed of
two trans-complementing, propagation-deficient VSV vec-
tors. The de novo generated deletion mutants of the two
VSV polymerase proteins P (phosphoprotein) and L (large
catalytic subunit), VSVΔP and VSVΔL respectively, were
used mutually or in combination with VSVΔG vectors. These
srVSV systems copropagated in vitro and in vivo without
recombinatory reversion to replication-competent virus. The
srVSV systems were highly lytic for human glioblastoma cell
lines, spheroids, and subcutaneous xenografts. Especially the
combination of VSVΔG/VSVΔL vectors was as potent as
wild-type VSV (VSV-WT) in vitro and induced long-term
tumor regression in vivo without any associated adverse
effects. In contrast, 90% of VSV-WT-treated animals suc-
cumbed to neurological disease shortly after tumor clearance.
Most importantly, evenwhen injected into the brain, VSVΔG/
VSVΔL did not show any neurotoxicity. In conclusion,
srVSV is a promising platform for virotherapeutic approaches
and also for VSV-based vector vaccines, combining improved
safety with an increased coding capacity for therapeutic
transgenes, potentially allowing for multipronged approaches.
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Introduction
The use of viruses as targeted cancer therapeutics has shown
significant promise in the last few years. Especially the
vesicular stomatitis virus (VSV), a relatively new player in
the oncolytic virotherapy field, has proven to be effective
against a variety of tumor entities such as malignant glioma
[1, 2], hepatocellular carcinoma [3, 4], prostate cancer [5, 6],
and ovarian carcinoma [7]. However, to date, the inherent
neurotoxicity of VSV has hindered clinical development
since intracerebral administration causes fatal encephalitis
in rodents and nonhuman primates [8, 9]. Thus, replication-
competent VSV is associated with an increased risk of
systemic dissemination and potentially severe pathology if
it enters the CNS. Therefore, attenuated virus variants and
propagation-deficient viral vectors were generated. Unfor-
tunately, the reduced toxicity of attenuated replication-
competent VSV is invariably accompanied with some re-
duction of replicative and oncolytic activity [10, 11], whereas
the major limitation of propagation-deficient viral vectors has
been the inefficient transduction rate of cancer cells in vivo
[2, 12].
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A new strategy to potentially enhance safety of replication-
competent VSV while increasing the capacity for therapeu-
tic transgenes is the use of a semireplication-competent
vector system similar to those described for retroviruses
and adenoviruses [13, 14]. Here, we successfully developed
a semireplication-competent vector system for VSV
(srVSV), which is based on two trans-complementing
propagation-deficient VSV vectors. The genes essential for
viral replication are divided onto two separate packageable
vector genomes, so that infectious progeny can only be
produced in double-infected host cells. Importantly, the
VSV RNA genome does not undergo genetic reassortment
or recombination, making it unlikely that the binary system
reverts into a replication-competent recombinant VSV [15].
In this study, we used the propagation-deficient, eGFP-
expressing VSV*ΔG-vector [16], which lacks the G gene,
in combination with de novo synthesized and rescued de-
letion mutants VSVΔP-DsRed and VSVΔL-DsRed, lack-
ing the genes P and L, respectively, that encode the
components of the viral polymerase complex. Accordingly,
three different srVSV combinations were feasible:
VSV*ΔG/VSVΔP-DsRed (srVSV(ΔG/ΔP)), VSV*ΔG/
VSVΔL-DsRed (srVSV(ΔG/ΔL)), and VSVΔP-DsRed/
VSVΔL-DsRed (srVSV(ΔP/ΔL)). All srVSV systems
allowed for in vitro reciprocal complementation thus lead-
ing to copropagation associated with clear antitumor poten-
cy against human glioblastoma cell lines. In addition, the
most potent vector combination, srVSV(ΔG/ΔL), was test-
ed in a preclinical subcutaneous (s.c.) glioblastoma mouse
model and proved to be only slightly attenuated compared
to wild-type VSV (VSV-WT). Tumors regressed in both
cohorts, but in contrast to the srVSV-treated group, 90% of
VSV-WT-treated animals succumbed to viral neurotoxicity.
Most importantly, neither srVSV treatment of tumor-
bearing animals nor direct intracranial administration in
healthy mice was associated with any sign of neurotoxicity.
Eventually, all srVSV systems proved to be safe as we
have not been able to detect any sign of recombinatory
reversion to the wild-type strain.
Materials and methods
Cell culture
BHK-21 baby hamster kidney and U-87 MG human glioblas-
toma cells were obtained from the American Type Culture
Collection (Manassas, VA). G62 human glioblastoma cells
were kindly provided by M. Westphal (University Hospital
Eppendorf, Hamburg, Germany). HEK 293-NPeGFPL (clone
206) stably expressing VSV-N, P, and L protein were a gift
fromA. Pattnaik (University of Nebraska, Lincoln, USA) [17].
All cells were kept in a humidified atmosphere containing 5%
CO2 at 37°C. BHK-21, U-87 MG, G62, and 293-NPeGFPL
cells were maintained in DMEM (Gibco) supplemented with
10% FBS (Perbio Science). 293-NPeGFPL cells were kept
under G418 selection.
Viruses
The propagation-incompetent VSV*ΔG vector, coding for
eGFP as reporter, as well as the particularly strong type I
interferon (IFN) inducing VSV*MQ, a replication-
competent VSV with multimutated matrix protein (VSV-
M), have been described previously [16, 18]. The deletion
mutants VSVΔP-DsRed and VSVΔL-DsRed were generat-
ed de novo: To exchange the VSV-P gene for DsRed, the N-
P intergenic region (IGR) and a part of the VSV-N gene as
well as the P-M IGR and a part of the M gene were PCR
amplified from pVSV-XN2 using the primers 5′-CGATC
TCGAGGTATACATCTCTTACTACAGCAGG-3 ′/5′-
CAGTGAATTCGATATCTGTTAGTTTTTTTCATATG
TAGC-3′ (N-P IGR) and 5′-CGATGCGGCCGCACTAT
GAAAAAAAGTAACAGATATCACG-3′/5′-CAGTCCGC
GGACGCGTAAACAGATCGATCTCTG-3′ (P-M IGR)
with unique restriction sites (shown in bold). In parallel,
DsRed was subcloned from pDsRed-Express-N1 (Clontech)
into the multiple cloning site (MCS) of the pBluescript-II
cloning vector (Stratagene) with BamHI/NotI. Subsequently,
PCR products were digested with XhoI/EcoRI (N-P IGR)
and NotI/SacII (P-M IGR) and sequentially cloned in front
and behind the DsRed gene. Finally, the DsRed cassette was
excised with BstZ17i/MluI and inserted into the BstZ17i/
MluI site of pVSV-XN2, replacing VSV-P to yield
pVSVΔP-DsRed. A similar cloning strategy was applied
to generate pVSVΔL-DsRed: The G-L IGR and a part of
the VSV-G gene as well as the L-HDV ribozyme region
were PCR amplified from pVSV-XN2 using the primers 5′-
CAGTGGTACCCTAAAATACTTTGAGACCAG-3′/5′-
C G ATGGATCCGAT T G C T G T TA G T T T T T T
TCATAAAAATTAAAAACTC-3′ (G-L IGR) and 5′-
CAGTGCGGCCGCAAAATCATGAGGAGACTC
CAAACTTTAAG-3 ′/5 ′-CGATGAGCTCGCACTAG
TATCGAGGTCTCGATC-3′ (L-HDV ribozyme) with
unique restriction sites (shown in bold). PCR products were
digested with KpnI/BamHI (G-L IGR) and NotI/SacI
(L-HDV ribozyme) and cloned in front and behind the
DsRed gene in the pBluescript-II-DsRed vector. Finally,
DsRed was excised with NheI/SpeI and inserted into the
NheI/SpeI site of pVSV-XN2, yielding pVSVΔL-DsRed.
Novel recombinant viruses (Fig. 1a) were rescued as described
previously [19]. To produce infectious virions, VSV*ΔG-vec-
tors were propagated on BHK-21 cells transiently expressing
VSV-G [20]. VSVΔP-DsRed and VSVΔL-DsRed were am-
plified on 293-NPeGFPL cells. Vector titers were determined
as 50% tissue culture infective dose (TCID50) using the
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Spearman–Kärber method [21]. VSVΔP-DsRed and
VSVΔL-DsRed titration was performed on 293-NPeGFPL
cells, VSV-WT and VSV*MQ were titrated on BHK-21 cells,
and VSV*ΔG titration was performed on BHK-GP [20].
Quantitative PCR-based multicycle growth curve analysis
BHK-21 cells were infected in 6-well plates (106 cells/well)
with a multiplicity of infection (MOI) of 0.05 of each
individual vector of the three potential srVSV vector sys-
tems or VSV-WT as positive control. Filtered (0.45 μm)
supernatants were collected at the indicated time points,
and RNA was extracted from 50 μl supernatant using the
RNeasy Mini Kit (Qiagen). RNA was reverse transcribed
using the High Capacity RNA-to-cDNA Kit (Applied Bio-
systems). Vector propagation was monitored via real-time
RT-PCR to determine the total VSV genomic RNA (gRNA)
amount in supernatants [19]. Known plasmid amounts were
used to determine the standard curve for real-time RNA
quantification. Two independent qPCR primer and probe
sets were used, spanning the N-P and the M-G IGR of the
VSV genome (see Supplementary Fig. S1c, d). Real-time
PCR was carried out with the TaqMan® Gene Expression
Master Mix (Applied Biosystems) using a LightCycler®
480 Real-Time PCR System (Roche). For both applied
real-time PCRs, the detection limit was 102 gRNA/ml.
In vitro cytotoxicity assay
Human glioblastoma cells were plated in 96-well plates at
104 cells/well in 100 μl medium. Cells were cultured as
monolayer or multicellular tumor spheroids. For spheroid
cultures, 96-well plates were precoated with 75 μl 1% agar
noble (Difco). Cultures were infected with the respective
viral system (srVSV or VSV-WT) at an MOI of 0.2 or
treated with phosphate-buffered saline (PBS) the following
day. Cell viability was assayed in dodecaplicates in n03
independent experiments at the indicated time points post-
infection using the cell proliferation agent WST-1 (Roche).
Results are expressed as percentage of viable cells compared
to PBS-treated controls.
Animal studies
For antitumor efficacy testing, 6-week old NOD/SCID mice
(Jackson Laboratories) were anesthetized with isoflurane and
106 G62 human glioblastoma cells were subcutaneously
injected into the left and right flanks. Tumor growth was
monitored with a caliper. At a tumor volume of 0.1 cm3, mice
were treated intratumorally with two doses of either 2.8×105
TCID50 srVSV(ΔG/ΔL) or 2.8×10
5 TCID50 VSV-WT and
PBS as controls. Bilateral tumors were treated alike. When
tumor size exceeded 0.8 cm3, mice were sacrificed. In addition,
two mice were sacrificed at 3 days post-srVSV treatment and
s.c. tumors were prepared for immunofluorescence analysis.
For neurotoxicity analysis, 6-week old CD1 Swiss mice
(Charles River) were anesthetized by intraperitoneal injection
of ketamine/xylazine (100 and 10 mg/kg of body weight,
respectively). 102, 103, and 104 TCID50 srVSV(ΔG/ΔL), as
well as 1.4×101 and 1.4×104 TCID50 VSV-WT or PBS were
stereotactically injected into the right frontal lobe of mice
brains (1.5 mm lateral, 2 mm rostral to the bregma at 2 mm
Fig. 1 Construction and functional characterization of srVSV systems. a
Schematic representation of the recombinant vesicular stomatitis virus
(VSV) genomes. Genomes and the respective open reading frames are
presented in 3′-5′ orientation. b Multicycle growth curves of srVSV
systems compared to VSV-WT. BHK-21 cells were infected with VSV-
WTor the respective srVSV systems at an MOI of 0.05. At the indicated
time points postinfection, culture supernatants were collected and viral
genomic RNAwas determined by real-time RT-PCR. Virus titers of n02
infection experiments are shown as mean±SD. c Symmetry of individual
vector genome contributions during copropagation was assessed via real-
time RT-PCR using two independent primer/probe sets. Ratios of indi-
vidual vector titers per total vector concentration are shown as mean±SD
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depth). Animals were monitored for signs of neurological
impairment. Two mice of the 104 TCID50 srVSV(ΔG/ΔL)-
treated group were sacrificed at 3 days postinjection (dpi), and
brains were prepared for immunofluorescence analysis. The
brains were sectioned (40 μm) on a Leica VT1000S vibratome
(Leica, Bensheim, Germany). Nuclear counterstaining was
performed with TO-PRO-3 iodide (Invitrogen). Sections were
analyzed by confocal laser scanning microscopy using a
Nikon C1S1 microscope (Nikon, Düsseldorf, Germany). All
procedures were approved by the governmental board for the
care of animal subjects (Regierungspräsidium Darmstadt,
Germany).
Stimulation and IFN-α detection
Murine bone marrow (BM)-derived plasmacytoid dendritic
cells (pDCs) were generated as previously described [22]. In
brief, BM cells were flushed from femur and tibia with RPMI
supplemented with 10% FBS (Perbio Science). Erythrocytes
were lysed, cells were washed, and single-cell suspensions
were cultivated for 8 days in medium supplemented with
100 ng/ml Flt3-L (R&D Systems). As determined by FACS
analysis, Flt3-L cultures consisted of ≈20% CD11c+B220+
pDCs (data not shown). For IFN stimulation experiments,
2×106 Flt3-L-stimulated BM-pDC bulk culture cells were
seeded per 24 well. Cultures were infected with either srVSV,
VSV*ΔG, VSVΔL-DsRed, VSV-WT, or VSV*MQ (each n0
2) at an MOI of 2. Supernatants were collected at 24 h post-
infection (hpi) and analyzed for IFN-α via ELISA (PBL
Biomedical Laboratories).
Statistical analysis
For comparison of individual time points or columns, statisti-
cal difference was determined using unpaired t test. Mice
survival curves were plotted as Kaplan–Meier analysis, and
statistical significance between treatment groups was com-
pared using the log-rank test.
Results
Novel recombinant viruses were cloned based on the pVSV-
XN2 plasmid background and rescued as described previ-
ously [19]. A schematic representation of the VSV vector
genomes is shown in Fig. 1a, and their identity was con-
firmed by gene-specific RT-PCR (Supplementary Fig. S1a,
b). Both deletion mutants, VSVΔP-DsRed and VSVΔL-
DsRed, were unable to propagate and did not generate
progeny virions in cell cultures not providing the respective
deleted viral gene in trans, as real-time RT-PCR (Supple-
mentary Fig. S1c, d) of supernatants were negative for VSV
gRNA (data not shown).
srVSV(ΔG/ΔL) is the most potent srVSV system in terms of
vector propagation In order to assess the replication com-
petence of the three potential srVSV systems, BHK-21 cells
were infected with an MOI of 0.05 of each individual vector
or VSV-WTas control to generate multicycle growth curves.
Vector propagation was monitored on the gRNA level via
real-time RT-PCR [19]. In VSV-WT-infected cultures,
gRNA associated with secreted progeny virions was first
detectable at 6 hpi, reaching a plateau around 12–18 hpi
with maximum titers of more than 8×108 gRNA/ml (8.77×
108±9.28×107 gRNA/ml, see Fig. 1b). In comparison, all
srVSV vector systems showed an earlier onset of replication
with first gRNA detectable at 3 hpi and srVSV(ΔP/ΔL)
being the most potent in the initial phase with titers of 5.33×
104±3.05×103 gRNA/ml 3 hpi. Both, the srVSV(ΔP/ΔG)
and the srVSV(ΔG/ΔL) system lagged behind with titers
being about tenfold reduced 3–6 hpi. Consistently, srVSV
(ΔP/ΔL) was also the first to reach its plateau at 10–12 hpi
with a maximum of 8.44×107±3.63×106 gRNA/ml before
its titer slowly started to regress. In contrast, both srVSV
(ΔP/ΔG) and srVSV(ΔG/ΔL) ended up with a more robust
replication, reaching titers of 1.19×108±1.63×106 gRNA/
ml for srVSV(ΔP/ΔG) and 7.60×108±4.47×107 gRNA/ml
for srVSV(ΔG/ΔL) at 24 hpi. Thus, the binary system using
VSV*ΔG and VSVΔL-DsRed was the most potent srVSV
system in terms of vector dissemination even reaching max-
imum gRNA titers comparable to VSV-WT.
In parallel, srVSV functional titers of supernatants col-
lected at 24 hpi were determined as TCID50 per milliliter, as
double-infected cells are a prerequisite to initiate copropa-
gation. Correspondingly, the TCID50 of srVSV systems
were 180- (srVSV(ΔG/ΔL)) to 2,000-fold (srVSV(ΔP/
ΔL)) lower than their gRNA titers, primarily reflecting the
chance of coinfection, and to a considerably lesser extent
reflecting the difference between genome and functional
titers, as VSV-WT gRNA titers were only 6-fold higher
compared to the respective TCID50. However, consistent
with the maximum obtained VSV gRNA per milliliter con-
centrations during the multicycle growth curve, srVSV(ΔG/
ΔL) displayed the highest TCID50 per milliliter of 4.22×
106, whereas titers for srVSV(ΔP/ΔG) were approx. 20-fold
and for srVSV(ΔP/ΔL) around 100-fold lower (Table 1).
srVSV systems are characterized by asymmetric copropaga-
tion As srVSV systems are composed of two vectors with
Table 1 Functional
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different properties such as gene composition and genome
size, the mode of copropagation during the multicycle growth
curve was analyzed via two independent qPCRs with ampli-
cons spanning the N-P or M-G IGR of the VSV genome
(Supplementary Fig. S1c, d). Combining the obtained qPCR
data, single-vector titers were calculated as ratio of the indi-
vidual vector gRNA per milliliter per total vector gRNA per
milliliter for all time points of the multicycle growth curve. As
ratios proved to be consistent for each srVSV system through-
out the whole observation period of 24 h, time-independent
means and standard deviations were calculated. Indeed, the
assessment revealed that vector copropagation was not due to
symmetric replication of both vector genomes, but could
rather be characterized as an asymmetric process (Fig. 1c).
Each srVSV system could be defined by a distinct preference
of one vector over the other. In case of srVSV(ΔP/ΔG), the
VSVΔP vector accounts for 65.49±2.16% and VSVΔG for
34.51±2.16% of the total titer. Even more pronounced is the
asymmetry in favor of the VSVΔL vector with a share of
65.99±6.78% (ΔP/ΔL) and 99.55±14.03% (ΔG/ΔL) of the
total progeny generated.
Time lapse fluorescence microscopy of srVSV(ΔG/ΔL) cop-
ropagation In a separate experiment, srVSV(ΔG/ΔL) cop-
ropagation was monitored by fluorescence time lapse
microscopy over a period of 24 h after infecting BHK-21
cells at an MOI of 0.05 (Supplementary Video S1). As nega-
tive control, BHK-21 cells were infected with VSV*ΔG only.
Representative micrographs at 0, 6, 12, 18, and 24 hpi are
shown in Fig. 2. First eGFP fluorescence was detectable at 6
hpi, whereas both, DsRed-fluorescence and cytopathic effects
(CPE), were confined to the srVSV-treated culture and were
not detectable prior to 12 hpi (Fig. 2a). The dissemination of
the srVSV system could be tracked by a gradual increase in
eGFP+/DsRed+ cells as well as progressing CPE reaching a
maximum at 24 hpi. In contrast, single-vector infected cultures
did not show any propagation with only single-infected eGFP+
cells detectable throughout the observation period (see Fig. 2b
and Supplementary Video S2).
srVSV shows no sign of recombinatory reversion to replication
competence The main idea to develop srVSV for oncolytic
virotherapy is to increase the integral safety compared to the
Fig. 2 Copropagation of srVSV(ΔG/ΔL) in vitro. BHK-21 cells were
infected with either a both defective VSV vectors or b only VSV*ΔG
at an MOI of 0.05 and monitored by fluorescence time lapse
microscopy for 24 h. Representative micrographs taken at the indicated
time points are shown (time lapsemovies are published as Supplementary
Videos S1 and S2)
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replication-competent counterpart. Accordingly, genomic
stability is an absolute requirement so that a recombinatory
reversion of the binary system, potentially restoring full
replicative capacity, can be precluded. In order to study viral
genome stability, srVSV systems were subjected to end
point dilution passage on BHK-21 cells to enable enrich-
ment of potential functional revertants analogous to Taucher
et al. [23]. To test this experimental setup, the srVSV sys-
tems were spiked with ten TCID50 VSV-WT as internal
control to see whether the replication-competent virus can
selectively be enriched. Already after passage 2 for srVSV
(ΔP/ΔL), passage 3 for srVSV(ΔP/ΔG), and passage 4 at
limiting dilutions for srVSV(ΔG/ΔL), the control-treated
BHK-21 cells showed virus-induced CPE at low supernatant
concentrations (down to 10−7) without any fluorescence de-
tectable. In comparison, the unspiked srVSV vector systems
copropagated only at high supernatant concentrations (down
to 10−4), whereas only single-positive cells were found in
cultures treated with low concentrations (down to 10−6). After
20 consecutive passages, serial dilutions of srVSV superna-
tants were tested for the number of focus-forming units via
plaque assay on BHK-21 cells. All srVSV systems formed
eGFP+/DsRed+ foci at high supernatant concentrations (down
to 10−4) with its number not being directly proportional to the
respective concentration. Instead, the interdependency be-
tween supernatant concentration and focus number could be
characterized by a nonlinear biphasic decay with a goodness
of fit of R200.99 (ΔG/ΔL), R200.99 (ΔP/ΔG), and R201.00
(ΔP/ΔL, Fig. 3a), respectively. This is in absolute accordance
with two individual replication-defective viral vectors consti-
tuting the copropagation-initializing unit. In comparison, the
interdependency for the respective spiking controls as well as
VSV-WT could be fitted by linear regression (R2 in between
0.99 and 1.0), as would be expected for a replication-
competent virus.
Next, we also looked directly for potential recombination
events by RT-PCR as a more sensitive means. cDNA of the
20th passage of the srVSV systems and the respective
spiking controls was prepared and used to perform a nested
PCR. The outer PCR selectively amplified the genome of
one recombinant vector out of the binary system as the
reverse primer binding site is constituted in the gene dele-
tion of the other vector genome (Supplementary Fig. S2).
For srVSV(ΔG/ΔL) the VSV*ΔG genome was amplified,
whereas for srVSV(ΔP/ΔG) and srVSV(ΔP/ΔL) the
VSVΔP-DsRed genome was amplified. The inner VSV
gene-specific PCRs then allowed us to check for potential
recombination events at the locus of the actual gene
Fig. 3 srVSV systems did not revert to full replication competence
after 20 consecutive passages at limiting dilutions. srVSV vector pairs
were subjected to repeated passaging (20 passages) on BHK-21 cells at
limiting dilutions. As positive control, srVSV systems were spiked
with ten TCID50 VSV-WT. At passage 20, serial dilutions of culture
supernatants were tested for recombinants via plaque assay and viral
RNAwas isolated and reverse transcribed. a Supernatant concentration
dependence of the number of formed foci. Serial dilutions of super-
natants were tested in triplicates (n03) and number of foci is shown as
mean±SD. Data points were fitted with either linear regression for
VSV-WT and spike controls or nonlinear regression (biphasic decay)
for srVSV systems. b Direct testing for potential recombination was
performed via VSV gene deletion specific analytical nested PCR.
Agarose gel electrophoresis of the obtained amplicons is shown
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deletion. Consistent with the phenotypic analysis (Fig. 3a),
we have not been able to detect any recombination event for
the srVSV systems. The VSV-G (for srVSV(ΔG/ΔL)) and
VSV-P gene (for srVSV(ΔP/ΔG) and srVSV(ΔP/ΔL))
were not detectable, whereas the according amplicons were
detected for the spiking control (see Fig. 3b). These data
were corroborated by sequence analysis of the outer PCR
amplicons, which clearly evidenced presence of the respective
fluorescence marker gene (data not shown). Thus, in both, the
phenotypic and genotypic analysis, recombination among the
vector genomes was not detectablewhile the respective spiking
controls were positive, the latter validating the applicability of
the applied assays.
srVSV exhibits antitumor activity in vitro and in vivo Since
the srVSV systems are to be used therapeutically as anti-
cancer agents, we assessed its antitumor potency against two
different human glioblastoma cell lines, G62 and U87, in
vitro as well as in a s.c. G62 xenograft model in vivo. G62
and U87 cells were infected at an MOI of 0.2 with the
respective viral system, and cell viability was monitored
compared to untreated controls using the WST-1 assay. In
addition to monolayer cultures (Fig. 4a), multicellular sphe-
roids of both cell lines were also used (Fig. 4b), as spheroids
represent an appropriate in vitro simulation of solid three-
dimensional tumors resembling some of its regional hetero-
geneity also found in vivo [24, 25]. In the initial phase at 24
hpi, no significant differences in cell viability could be
observed for U87 cells treated with the different viral sys-
tems. On the other hand, srVSV-treated G62 cultures
showed significant differences compared to VSV-WT
(98.69±5.59% survival) initially at 24 hpi: G62 monolayers
were reduced in cell viability for srVSV(ΔG/ΔL) (88.97±
3.55% survival) and srVSV (ΔP/ΔL) (80.25±8.87% survi-
val, both p<0.01; Fig. 4a), whereas G62 spheroids showed
increased cytopathic effects for all three srVSV systems
tested relative to VSV-WT (p<0.01, Fig. 4b). At all other
time points (48–120 hpi), infected glioma cultures showed
gradual reduction of cell viability due to viral CPE. For G62
monolayer cultures, srVSV(ΔG/ΔL) and srVSV(ΔP/ΔL)
were as potent as VSV-WT. In contrast, srVSV(ΔP/ΔG)
showed significantly reduced antitumor efficacy compared
to all other viral systems (p<0.001). Similar results were
obtained for G62 spheroid cultures, with srVSV(ΔP/ΔG)
lagging behind in its cytotoxicity (p<0.001) and srVSV
(ΔP/ΔL) being the most potent closely followed by
srVSV(ΔG/ΔL). For U87 cultures, differences in cell via-
bility between different treatment groups were not as strong:
Fig. 4 srVSV is comparable to
VSV-WT with regard to its in
vitro antitumor efficacy. a G62
and U87 human glioblastoma
cells were infected with srVSV
or VSV-WT at an MOI of 0.2.
Cell viability was assayed at the
indicated time points via
WST-1 assay compared to
untreated controls. b G62 and
U87 human glioblastoma cells
were grown as multicellular
spheroids on agar. After sphe-
roids had formed, cultures were
infected with srVSV or VSV-
WT at an MOI of 0.2. Cell
viability was assayed at the
indicated time points via
WST-1 assay compared to
untreated controls. Bars show
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srVSV(ΔP/ΔG)-treated cultures were clearly the most via-
ble (ranging from p<0.01 to p<0.001), whereas the srVSV
(ΔG/ΔL) system performed best with regard to its antitu-
mor effect. However, all srVSV-treated groups showed
attenuated antitumor efficacy compared to VSV-WT-treated
cultures.
To determine whether srVSV is also effective in vivo, the
most promising srVSV system, srVSV(ΔG/ΔL), was di-
rectly injected into s.c. bilateral G62 tumor xenografts at
2.8×105 TCID50. Control tumors were either injected with
PBS or 2.8×105 TCID50 VSV-WT. PBS-treated tumors
grew rapidly, and all mice had to be sacrificed before
day 53 posttransplantation with a median survival of 50 days
posttransplantation (dpt; Fig. 5a, c). In contrast, VSV-WT-
treated mice showed a 100% tumor response rate associated
with rapid reduction of tumor burden. Fourteen out of 20
(70%) VSV-WT-injected tumors (two tumors per mouse)
regressed completely, but unfortunately 9 out of 10 (90%)
VSV-WT-treated mice developed severe neurological symp-
toms (e.g., hind pawn paralysis, circulation, apathy) and had
to be sacrificed, leading to a median survival of 43 dpt. Only
one VSV-WT-treated mouse showed long-term event-free
survival. In the srVSV-treated cohort, all tumors responded
and regressed over time as well (Fig. 5a). Consistently, s.c.
tumors isolated 3 days posttreatment showed multiple foci
of copropagation throughout the tumor diameter (Fig. 5b).
But in contrast to VSV-WT, antitumor efficacy was
attenuated as tumors regressed slower with first significant
differences detectable at 31 dpt (p<0.001). However, at
80 days posttreatment (100 dpt), 16 out of 20 tumors
(80%) were eliminated and all other tumors were continu-
ously regressing. Most importantly, all srVSV-treated mice
did not show any adverse effects, so that srVSV treatment
eventually led to long-term survival compared to both control
cohorts (p<0.0001, Fig. 5c).
srVSV(ΔG/ΔL) exhibits reduced neurotoxicity compared to
VSV-WT With srVSV(ΔG/ΔL) having shown potent anti-
tumor activity in vitro and in vivo, its toxicity profile was
evaluated after direct intracerebral administration. Mice
were inoculated with either escalating doses of 102 (n03),
103 (n04), and 104 (n07) TCID50 srVSV(ΔG/ΔL) or 1.4×
101 and 1.4×104 TCID50 VSV-WT (each, n08) or PBS (n0
8), respectively. Mice were monitored for signs of neuro-
toxicity over a period of 40 days (Fig. 6a). Two mice of the
high-dose srVSV group were sacrificed at 3 dpi, and in vivo
copropagation was found to be restricted to the needle track
and its proximity by immunofluorescence analysis (Fig. 6b).
Most importantly, none of the srVSV(ΔG/ΔL)-injected ani-
mals showed any evidence of neuropathology with 100% of
animals surviving to the end point as did the PBS-injected
negative control cohort. In striking contrast, both the low-
and high-dose VSV-WT cohort developed neuropathology
within 2–9 dpi with all mice succumbing to neurological
Fig. 5 srVSV shows
copropagation in vivo leading
to antitumor activity without
adverse effects. NOD/SCID
mice were subcutaneously
transplanted with 106 G62
human glioblastoma cells per
flank. At a tumor size of
approximately 0.1 cm3, tumors
were either treated with PBS,
2.8×105 TCID50 VSV-WT or
2.8×105 TCID50 srVSV(ΔG/
ΔL). a Tumor growth was
assessed with a caliper. Mice
with tumors exceeding 0.8 cm3
were sacrificed. b Two
representative srVSV-treated
mice were sacrificed at 3 dpi,
tumors were removed and sus-
pended in PBS/4% paraformal-
dehyde. Tumor sections
(40 μm) were prepared and nu-
clear counterstaining was per-
formed with TO-PRO-3 iodide.
c Kaplan–Meier survival analy-
sis of the respective treatment
groups. **p<0.01, ***p<
0.001. i.t. intratumoral, arrow
injection site
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symptoms by day 9 and a median survival of 4.5 dpi (1.4×
104 TCID50 VSV-WT) and 7.5 dpi (1.4×10
1 TCID50 VSV-
WT), respectively. Hence, neurotoxicity of srVSV(ΔG/ΔL)
was at least >700-fold reduced if compared to VSV-WT
with differences in survival between srVSV- and VSV-
WT-treated cohorts being highly significant (p<0.001).
srVSV(ΔG/ΔL) is a potent type I IFN inducer As it was
previously shown that type I IFN-inducing strains of VSV
were strongly attenuated regarding their toxicity [26], the
capacity of srVSV(ΔG/ΔL) to induce IFN was evaluated in
murine pDC cultures. pDCs were infected with either
srVSV(ΔG/ΔL), VSV*ΔG, VSVΔL-DsRed, or VSV-WT
as negative and VSV*MQ as positive control at an MOI of 2.
Culture supernatants were collected at 24 hpi and analyzed
for IFN-α via ELISA. Unsurprisingly, the VSV-M multi-
mutated positive control VSV*MQ induced the strongest
type I IFN response, with 3,200.11±57.02 pg IFN-α per ml
supernatant, whereas VSV-WT treatment induced 18-fold
lower amounts (174.47±16.70 pg/ml; p<0.0001), being con-
sistent with Waibler et al. [22]. In striking contrast to VSV-
WT, srVSV(ΔG/ΔL) proved to be a very potent type I IFN
inducer with significantly elevated IFN-α levels of 1,035.52±
50.57 pg/ml (p<0.0001). However, single-vector treatment
with propagation-deficient VSV*ΔG and VSVΔL-DsRed
induced only basal IFN-α levels.
Discussion
Here, we developed a semireplication-competent VSV vector
system composed of two separate propagation-incompetent
viral vectors that shows significant anticancer activity without
the neurotoxicity usually found in VSV infection of mice and
nonhuman primates. Three different vector pairs of three
separate propagation-incompetent vectors VSVΔP-DsRed,
VSV*ΔG, and VSVΔL-DsRed were feasible, and all three
combinations were able to effectively trans-complement each
other and generate progeny virions (Figs. 1b, c and 2 and
Table 1).
The combination of VSV*ΔG and VSVΔL-DsRed
proved to be the most potent in terms of vector propagation
(Fig. 1b, Table 1) and in vitro antitumor efficacy (Fig. 4),
being only slightly attenuated compared to VSV-WT. That
this combination outperforms the other srVSV systems is
most likely due to the small genome size of the VSV-L gene
deleted VSVΔL-DsRed vector (5.6 kB, Fig. 1a). Compared
to full-length VSV, the smaller sized VSVΔL-DsRed ge-
nome is statistically favored for replication, packaging, and
viral shedding. This is consistent with VSV-defective interfer-
ing particles, as apart from the 5′–3′ terminal complementarity
as major determinant, genome size was also shown to impact
their replicative dominance over VSV-WT [15, 27]. More-
over, the asymmetric contributions of either vector genome
and particularly the overrepresentation of VSVΔL-DsRed in
the srVSV(ΔG/ΔL) and the srVSV(ΔP/ΔL) system (Fig. 1c)
as well as the fact that both VSVΔL-DsRed containing srVSV
systems exhibit superior antitumor efficacy compared to
srVSV(ΔP/ΔG) (Fig. 4) can also be explained by the genome
size-dependent replicative advantage. In fact, despite the low
initial MOI of 0.2, coamplification led to a nearly complete
tumor cell killing in vitro at 96 hpi for glioma monolayer and
spheroid cultures, underscoring the strong oncolytic potential
of both srVSV(ΔG/ΔL) and srVSV(ΔP/ΔL). However, com-
pared to srVSV(ΔP/ΔL), the (ΔG/ΔL) combination proved
to be somewhat more potent in terms of vector propagation.
The VSV*ΔG vector, which lacks the ability to produce
infectious virus but still exhibits functional replication and
Fig. 6 srVSV exhibits reduced neurotoxicity relative to VSV-WT.
Escalating doses of 102, 103, and 104 TCID50 srVSV(ΔG/ΔL) as well
as 1.4×101 and 1.4×104 TCID50 VSV-WT or PBS were stereotacti-
cally injected into mouse brains. a Animals were monitored for signs
of neurological impairment for 40 days. As all srVSV-treated cohorts
showed event-free survival up to the end point, only the data set of the
high-dose srVSV-treated cohort is shown. b Two mice of the 104
TCID50 srVSV(ΔG/ΔL)-treated group were sacrificed at 3 dpi, brains
were fixed and sections (40 μm) prepared for immunofluorescence
analysis. Nuclear counterstaining was performed with TO-PRO-3
iodide. ***p<0.001, arrow injection site
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transcription, provides the L polymerase for immediate
VSVΔL-DsRed replication and transcription upon coinfec-
tion. This is opposed to srVSV(ΔP/ΔL), as here only
double-infected cells support efficient genome replication and
transcription, which might explain for the marginal reduced
replication competence of the latter system. Accordingly, the
most potent srVSV system, srVSV(ΔG/ΔL), was assessed for
its antitumor potency in a s.c. G62 human glioblastoma xeno-
graft model. All srVSV-treated tumors showed a clear response
starting at 2 dpi. Tumors regressed and viral dissemination
could be detected throughout the neoplastic tissue by immu-
nohistochemistry (Fig. 5a, b). Although, compared to VSV-
WT-treated mice tumor regression was significantly slower,
srVSV treatment was not associated with any severe adverse
effects (Fig. 5c). Whereas 90% of mostly (70%) tumor-free
VSV-WT-treated animals had to be euthanized due to neuro-
toxicity, srVSV treatment resulted in long-term survival of all
animals with 80% tumor clearance at 100 dpt compared to both
control cohorts. Thus, it can be assumed that replication of
srVSV is self-contained to the injection site and adjacent areas
of the topically treated tumor, reducing the risk of a systemic
infection or dissemination.
On the other hand, this intrinsic safety of binary srVSV
systems may reduce therapeutic efficacy upon systemic
application, as cells within target tissue need to be double
infected to trigger oncolytic copropagation in the tumor.
However, when delivered locoregionally, the srVSV system
indeed exhibits a vastly improved therapeutic index when
compared to VSV-WT, as even after direct intracerebral
administration of escalating viral doses into mouse brains
no toxicity could be observed. All srVSV-treated mice (low-
and high-dose cohorts) showed 100% event-free survival up to
the end point of the study (40 days, Fig. 6a). Again, immuno-
histochemistry of mice sacrificed at 3 dpi displayed locally
restricted srVSV copropagation at the needle track and its close
proximity (Fig. 6b). In contrast, both low- and high-dose
cohorts of VSV-WT-treated mice developed neurotoxicity
with a median survival of 7.5 dpi (1.4×101 TCID50) or even
4.5 dpi for the high-dose cohort (1.4×104 TCID50, Fig. 6a).
Hence, in direct comparison with VSV-WT, the srVSV-
associated neurotoxicity is at least >700-fold reduced while
retaining its potent oncolytic activity.
As infection of susceptible cells for both viral systems,
VSV-WT and srVSV, is mediated by the VSV-G envelope
protein, the attenuated phenotype of srVSV is not due to a
shift of tropism. Instead, our data emphasize two aspects,
which lead to a general and a more specific attenuation:
First, the srVSV intrinsic mode of replication leads to a
general attenuation per se, as copropagation is limited to
foci of high vector concentrations resulting in double-
infected cells and ongoing spread. At distal sites to the
replicating foci, vector concentrations dramatically decrease
particularly in solid tissue possibly ending off copropagation.
Consistently, discrete foci of copropagation could be observed
throughout the tumor diameter in intratumoral injected s.c.
tumors (Fig. 5b) as well as in mouse brains after intracranial
injection (Fig. 6b). Second, srVSV proved to be a very potent
type I IFN inducer, inducing at least 18-fold higher IFN-α
amounts when compared to VSV-WT (Fig. 7). Similar to the
IFN-inducing VSV strains AV1 and AV2, we expect srVSV
to be selectively attenuated in IFN-responsive, healthy cells
while retaining its lytic potential in IFN-deregulated neo-
plastic cells. However, in comparison with AV1 and AV2,
the ability to induce type I IFN is not attributed to a mutant
VSV-M, which blocks host nucleocytoplasmic mRNA ex-
port, as both components of the binary system code for
wild-type VSV-M [26]. In this regard we presume that due
to the gene deletions, the srVSV(ΔG/ΔL) coreplication
operates on a distorted transcription gradient with deficient
levels of VSV-G and VSV-L particularly in the initial phase
postinfection. These aberrant VSV protein levels may po-
tentially lead to a prolonged retention time of unassembled
virions within the host cell with the prolonged residence of
viral RNA eventually triggering pattern recognition recep-
tors, which can initiate a type I IFN response. The exact
reason for the IFN-inducing capability of srVSV as well as
its contribution to the overall attenuation of srVSV clearly
requires further analysis.
In addition, the srVSV systems were also safe with re-
spect to potential recombinatory reversion to a replication-
competent phenotype, as after 20 consecutive passages at
limiting dilutions, phenotypic and genotypic analyses were
negative for recombinant replication-competent virus, with
VSV-WT spiked positive controls validating the assays
(Fig. 3). This observation is also consistent with earlier studies
on the potential recombination between temperature-sensitive
VSV mutants [28].
Fig. 7 srVSV is a potent type I IFN inducer. Mouse plasmacytoid DC
cultures were infected at an MOI of 2 with either srVSV(ΔG/ΔL),
VSV*ΔG, VSVΔL-DsRed, VSV-WT, or the strongly type I IFN-
inducing VSV*MQ as a positive control (each n02). Culture super-
natants were collected at 24 hpi and analyzed for IFN-α via ELISA
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In summary, relative to VSV-WT, srVSV systems present a
promising platform for virotherapeutic approaches, as they are
genetically stable and exhibit considerably reduced neurotox-
icity while retaining their antitumor potency. Furthermore,
srVSV systems offer a strongly increased coding capacity so
that both viral vectors can be “armed” to express therapeutic
transgenes allowing for multipronged approaches, combining
their inherent oncolytic effect with a tumor microenvironment
modulating suicide and/or immunostimulatory “payload” to
boost antitumor potency. Eventually, with respect to both
biosafety and coding capacity, srVSV systems may not only
prove valuable for oncolytic virotherapy but also represent an
attractive vector vaccine platform.
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